The DTC Act of 2025 would require certain advertisements for prescription drugs and biological products to disclose their wholesale acquisition cost (WAC), or list price. The rule would apply to products covered by Medicare or Medicaid when their advertisements must already include information about side effects, contraindications, and effectiveness. Drugs with a WAC below $35 for a 30-day supply or typical treatment course would be exempt. The disclosure would need to be clear and noticeable. The bill would direct the Secretary of Health and Human Services to issue rules on how prices appear in audio and visual ads and how quickly ads must be updated when prices change. Manufacturers or their agents could face civil penalties of up to $100,000 for each violation.
If enacted, you may see the WAC in covered drug advertisements. The bill allows ads to explain that your actual cost may differ based on your insurance. The WAC is not necessarily the amount you would pay.
The bill authorizes sums as necessary to carry out its requirements but does not specify an amount. No publicly available information.
The bill states that price disclosures could help people compare prices, understand costs before starting treatment, and consider lower-cost alternatives. It also states that price information may support competition and more efficient Medicare spending.
No publicly available information.